RMD ResMed Inc.

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement.

For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company’s last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step – transforming into a fully unified health technology brand that serves millions of consumers, healthcare professionals, and software users worldwide.

An estimated 2.3+ billion people worldwide suffer from sleep apnea, insomnia, COPD, or other respiratory insufficiency. 1 2 3 Additionally, highlights the widespread impact of poor sleep, with one-third of respondents reporting sleep difficulties, including trouble falling asleep (34%) and staying asleep (29%).4 Through its brand evolution, Resmed accelerates its ability to reach people where they are – and help them sleep better, breathe better, and improve their overall health and well-being.

“We are at a pivotal moment in health – sleep and breathing health are gaining the attention once reserved for diet and exercise, with consumers taking a more proactive role in their care,” said Katrin Pucknat, Resmed’s Chief Marketing Officer. “Our brand evolution is more than a new look – it’s a bold step forward in our strategy to make sleep and breathing health a mainstream priority in global healthcare.”

As part of the brand evolution, Resmed plans to consolidate its brands, products, and services under a single Resmed brand over the next couple of years, creating a more streamlined view for both consumers and healthcare providers. This transformation is accompanied by a new visual identity, redesigned logo, and refreshed brand voice, reinforcing Resmed’s position as an approachable, people-centered, and forward-thinking health technology company.

The brand evolution aligns with Resmed’s mission to create life-changing health technologies that people love and coincides with three major market-facing initiatives aimed at reshaping perceptions of sleep therapy and expanding awareness of sleep apnea treatment:

  • The company’s first U.S. consumer campaign aimed at destigmatizing CPAP therapy and positioning sleep health as more approachable
  • A targeted primary care physician (PCP) education campaign starting in the U.S. to help drive earlier diagnosis and intervention for sleep apnea
  • A sleep health awareness campaign in key markets in Asia Pacific and Europe focused on helping to overcome the barriers to seeking treatment for sleep apnea

“Resmed has evolved beyond its origins as a CPAP device and mask manufacturer. Our new brand reflects who we are today – a global leader in health technology, delivering solutions that help people rise to their full potential through better sleep and breathing, with care delivered in the home,” said Mick Farrell, Resmed’s Chairman & CEO. “With this evolution, we are reaffirming our commitment to empowering 500 million people worldwide to achieve their full health potential by 2030 and changing the delivery of healthcare.”

To learn more about Resmed’s brand evolution, visit .

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at and follow @Resmed.

  
For Media For Investors
  
Julia MoserMike Ott or Wendy Wilson
 

_________________________________

1 Benjafield et al Lancet Respir Med 2019

2 Benjafield et al Sleep Med (suppl) 2024

3 Boers et al JAMA Network Open 2023

4 Based on over 30,000 respondents across 13 markets surveyed as part of the ResMed 2025 Global Sleep Survey between December 12-28, 2024)



EN
11/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

ResMed Inc: 1 director

A director at ResMed Inc sold 2,000 shares at 247.320USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Resmed Champions Sleep Health as The Official Sleep Partner of The Qat...

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans’ dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will b...

 PRESS RELEASE

Resmed Acquires VirtuOx

Resmed Acquires VirtuOx Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more a...

 PRESS RELEASE

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 202...

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin ...

 PRESS RELEASE

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Resmed Names Salli Schwartz as Chief Investor Relations Officer Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairm...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch